We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Targeting a Rare Brain Cancer With Spherical Nucleic Acids

The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the FDA as an investigational drug for clinical investigation in the deadly brain cancer glioblastoma multiforme. 

Related coverage: